Volume 8 Issue 1
Jan.  2017
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2017  >  8(1): 66-72
Zhuang Jie, Dai Bo, Wu Lijuan, et al. Clinical observation of hepatitis B virus carriers after renal transplantation[J]. ORGAN TRANSPLANTATION, 2017, 8(1): 66-72. doi: 10.3969/j.issn.1674-7445.2017.01.013
Citation: Zhuang Jie, Dai Bo, Wu Lijuan, et al. Clinical observation of hepatitis B virus carriers after renal transplantation[J]. ORGAN TRANSPLANTATION, 2017, 8(1): 66-72. doi: 10.3969/j.issn.1674-7445.2017.01.013
shu

Clinical observation of hepatitis B virus carriers after renal transplantation

doi: 10.3969/j.issn.1674-7445.2017.01.013

  • Clinical molecular diagnosis of laboratory medicine, West China Hospital, Sichuan University, Chengdu 610041, China

More Information
  • Corresponding author: Lin Tao, Email:kidney5@163.com
  • Received Date: 2016-10-15
    Available Online: 2021-01-19
  • Publish Date: 2017-01-15
    Abstract
  •   Objective  To observe the changes of liver and kidney function in hepatitis B virus (HBV) carriers after renal transplantation.  Methods  A total of 116 patients with HBV infection undergoing renal transplantation and 348 counterparts without HBV infection were recruited in this clinical trial. The liver function parameters including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and renal function parameter including serum creatinine (Scr) level were measured before and at 1, 3, 6, 12, 18, 24, 36 and 60 months after renal transplantation. Preoperative and postoperative changes of liver and kidney function were statistically compared between the hepatitis B surface antigen (HBsAg) (+) and HBsAg (-) groups. According to the results of preoperative HBV serology, preoperative quantitative detection of HBV DNA and preoperative liver function test, 116 HBsAg (+) patients undergoing renal transplantation were divided into (HBsAg, HBeAg and anti-HBc all positive) and (HBsAg, anti-HBe and anti-HBc all positive) groups, HBV DNA (+) and HBV DNA (-) groups, and normal and abnormal liver function groups. Preoperative and postoperative changes of liver and kidney function were statistically compared between different subgroups.  Results  (1) Preoperative ALT and AST levels in HBsAg (+) patients were significantly higher compared with those in their HBsAg (-) counterparts. In 36 months after renal transplantation, liver function parameters significantly differed between two groups (all P < 0.05), whereas no statistical significance was noted at postoperative 60 months (all P>0.05). Before and in 60 months after renal transplantation, no statistical significance was observed in the Scr levels between the HBsAg (+) and HBsAg (-) groups (all P>0.05). (2) Before and in 60 months after renal transplantation, no statistical significance was observed in the liver and kidney function parameters between the (HBsAg, HBeAg and anti-HBc all positive) and (HBsAg, anti-HBe and anti-HBc all positive) groups, and HBV DNA (+) and HBV DNA (-) groups (all P>0.05). (3) The ALT levels before and at 1, 3, 6 and 12 months after renal transplantation significantly differed between the normal and abnormal liver function groups (all P < 0.05), whereas no statistical significance was observed at other time points (all P>0.05). The AST levels before and at 1 month after renal transplantation significantly differed between two groups (both P < 0.05), whereas did not significantly differ at alternative postoperative time points (all P>0.05). No statistical significance was observed in the kidney function parameters before and at 60 months following renal transplantation between two groups (all P>0.05).  Conclusions  HBV infection cannot exert significant effect upon kidney function within 5 years after renal transplantation, whereas it can affect short-term postoperative liver function.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    Reddy PN, Sampaio MS, Kuo HT, et al. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1481-1487. DOI: 10.2215/CJN.09201010.
    [2]
    Tsai MC, Chen YT, Chien YS, et al. Hepatitis B virus infection and renal transplantation[J]. World J Gastroenterol, 2010, 16(31): 3878-3887. doi: 10.3748/wjg.v16.i31.3878
    [3]
    刘淑粉, 杨淑玲.乙肝病毒感染者肾移植术后肝功能损害的临床分析和随访管理[J].全科护理, 2015, (17): 1635-1637. DOI: 10.3969/j.issn. 1674-4748. 2015.17.024.

    Liu SF, Yang SL. Clinical analysis and follow-up management of liver function damage in patients with hepatitis B virus infection after kidney transplantation[J]. Chin Gen Pract Nurs, 2015, (17): 1635-1637.DOI: 10.3969/j.issn.1674-4748.2015.17.024.
    [4]
    石韶华, 王振兴, 陈花, 等.乙型肝炎病毒和丙型肝炎病毒感染对肾移植受者存活的影响[J].器官移植, 2012, 03(3): 159-162.DOI: 10.3969/j.issn.1674-7445.2012.03.008.

    Shi SH, Wang ZX, Chen H, et al. Influence of hepatitis B virus and hepatitis C virus infection on the survival of renal transplant recipients[J]. Organ Transplant, 2012, 3(3): 159-162.DOI: 10.3969/j.issn.1674-7445.2012.03.008.
    [5]
    Emori CT, Perez RM, Matos CA, et al. Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients[J]. Braz J Infect Dis, 2014, 18(6): 625-630. DOI: 10.1016/j.bjid.2014.06.004.
    [6]
    Maekawa H, Yazawa M, Koitabashi K, et al. Safety of monitoring viral and liver function markers in patients with prior resolved hepatitis B infection after kidney transplantation[J]. Transplant Proc, 2016, 48(6): 2046-2049. DOI: 10.1016/j.transproceed.2016.03.049.
    [7]
    Fabrizi F, Dulai G, Dixit V, et al. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials[J]. Transplantation, 2004, 77(6): 859-864. doi: 10.1097/01.TP.0000116448.97841.6D
    [8]
    刘勇, 杨亦荣, 郑少玲, 等.145例肾移植受者死亡原因分析[J].中华器官移植杂志, 2004, 25(4): 235-236. DOI: 10.3760/cma.j.issn.0254-1785.2004.04.015.

    Liu Y, Yang YR, Zheng SL, et al. Analysis of the death causes of 145 cases of renal transplant recipients[J]. Chin J Organ Transplant, 2004, 25(4): 235-236. DOI: 10.3760/cma.j.issn.0254-1785.2004.04.015.
    [9]
    Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients[J]. Hepatology, 2002, 36(5): 1246-1252. doi: 10.1053/jhep.2002.36156
    [10]
    Grenha V, Parada B, Ferreira C, et al. Hepatitis B virus, hepatitis C virus, and kidney transplant acute rejection and survival[J]. Transplant Proc, 2015, 47(4): 942-945. DOI: 10.1016/j.transproceed.2015.04.004.
    [11]
    Tuncer M, Tekin S, Yücetin L, et al. Hepatitis B surface antigen positivity is not a contraindication for living kidney donation[J]. Transplant Proc, 2012, 44(6): 1628-1629. DOI: 10.1016/j.transproceed.2012.04.015.
    [12]
    Lee J, Cho JH, Lee JS, et al. Pretransplant hepatitis B viral infection increases risk of death after kidney transplantation: a multicenter cohort study in korea[J]. Medicine (Baltimore), 2016, 95(21): e3671. DOI: 10.1097/MD.0000000000003671.
    [13]
    韩国锋, 胡大勇, 顾勇, 等.乙型肝炎病毒和丙型肝炎病毒感染对肾移植受者长期预后影响[J].中国临床医学, 2009, 16(3): 406-409. DOI: 10.3969/j.issn.1008-6358.2009.03.030.

    Han GF, Hu DY, Gu Y, et al. Impact of hepatitis B and hepatitis C virus infections on patients and allograft outcomes in renal transplant recipients[J]. Chin J Clin Med, 2009, 16(3): 406-409. DOI: 10.3969/j.issn.1008-6358.2009.03.030.
    [14]
    Kliem V, Burg M, Haller H, et al. Relationship of hepatitis B or C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data[J]. Transplant Proc, 2008, 40(4): 909-914. DOI: 10.1016/j.transproceed.2008.03.031.
    [15]
    汪东剑, 张晓云, 李志晋, 等. HBV-DNA与乙型肝炎血清标志物的相关性分析[J].现代生物医学进展, 2014, 14(3): 444-447. DOI: 10.13241/j.cnki.pmb. 2014.03.012.

    Wang DJ, Zhang XY, Li ZJ, et al. Analysis of the correlation between serum immune markers of hepatitis B virus and HBV-DNA[J]. Progr Mod Biomed, 2014, 14(3): 444-447. DOI: 10.13241/j.cnki.pmb.2014.03.012.
    [16]
    许龙根, 成军, 宋启哲, 等.血清乙型肝炎病毒标志物不同表现模式及肝功能异常对肾移植受者存活率的影响[J].中华器官移植杂志, 2002, 23(5): 281-283. DOI: 10.3760/cma.j.issn.0254-1785.2002.05.008.

    Xu LG, Cheng J, Song QZ, et al. Effect of varied Modes of serum hepatitis virus markers and liver dysfunction on the survival rate of the renal transplant recipients[J]. Chin J Organ Transplant, 2002, 23(5): 281-283. DOI: 10.3760/cma.j.issn.0254-1785.2002.05.008.
    [17]
    童强, 姚立欣, 羊继平, 等.肝炎病毒阳性患者肾移植术后肝损害的临床研究[J].东南国防医药, 2008, 10(2): 93-96. http://www.cnki.com.cn/Article/CJFDTOTAL-DNGY200802006.htm

    Tong Q, Yao LX, Yang JP, et al. Clinical research on the liver damage in the patients with viral hepatitis after renal transplantation[J]. Milit Med J Southeast Chin, 2008, 10(2): 93-96. http://www.cnki.com.cn/Article/CJFDTOTAL-DNGY200802006.htm
    [18]
    王庆文, 季曙明.慢性肝炎受者肾移植术前肝活检的临床价值[J].肾脏病与透析肾移植杂志, 2000, 9(3): 210-214. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY200003002.htm

    Wang QW, Ji SM. Liver biopsy in candidate renal graft recipients with chronic hepatitis[J]. Chin J Nephrol Dial Transpl, 2000, 9(3): 210-214. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY200003002.htm
    [19]
    丁振山, 杨志豪.肾移植患者感染乙肝病毒的抗病毒治疗[J].肾脏病与透析肾移植杂志, 2010, 19(1): 84-87.DOI: 10.3969/j.issn.1006-298X.2010.01.018.

    Ding ZS, Yang ZH. Antiviral treatment of hepatitis B virus infection in patients with renal transplantation[J]. Chin J Nephrol Dial Transpl, 2010, 19(1): 84-87. DOI: 10.3969/j.issn.1006-298X.2010.01.018.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (158) PDF downloads(6) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return